^
2d
Sincerely20: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (clinicaltrials.gov)
P2, N=51, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
Trial completion date • Trial primary completion date • IO biomarker • Epigenetic controller
|
PD-L1 expression
|
Tyvyt (sintilimab) • Epidaza (chidamide)
4d
New P2 trial • Combination therapy • Metastases
|
Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
4d
Prospective, open-label, phase II clinical study of the combination of Chidamide and Anlotinib ± PD-1/PD-L1 inhibitors in patients with SWI/SNF complex-deficient mutations (ChiCTR2400090522)
P2, N=57, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
New P2 trial • IO biomarker
|
ARID1A (AT-rich interaction domain 1A) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
|
Focus V (anlotinib) • Epidaza (chidamide)
4d
New P2 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
capecitabine • vinorelbine tartrate • Epidaza (chidamide)
4d
New P2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
|
gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)
9d
New P2 trial
|
Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • Epidaza (chidamide) • vindesine
10d
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (clinicaltrials.gov)
P1, N=26, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Talzenna (talazoparib) • Beleodaq (belinostat)
10d
Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function. (PubMed, Sci Rep)
Degradation of STAT3 by C210 enhanced the EBV-reactivating and anticancer capacity of suberoylanilide hydroxamic acid (SAHA). Depletion of XPB blocked SAHA-induced expression of late viral genes and production of infectious virions. These results elucidate a novel Hsp90 inhibitor targeting EBV lytic phase and extend the research on lytic induction strategy, which may offer reference value in the treatment of EBV-positive malignancies.
Journal
|
XBP1 (X-box-binding protein 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
Zolinza (vorinostat)
10d
The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response. (PubMed, Front Pharmacol)
Additionally, NOP58 was linked to drug responses, including Methotrexate, Rapamycin, Sorafenib, and Vorinostat. Its expression level serves as a reliable prognostic biomarker and an actionable therapeutic target, advancing precision medicine for prostate cancer. Targeting NOP58 may enhance therapeutic efficacy and improve outcomes in oncology.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
sorafenib • methotrexate • sirolimus • Zolinza (vorinostat)
10d
Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma. (PubMed, Ther Adv Hematol)
To evaluate the efficacy of a novel histone deacetylase inhibitor, chidamide, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (CR-CHOP) in the treatment of DEL. The most common grades 3-4 hematologic and nonhematologic toxicity were leukopenia (46.7%) and infection (21%), respectively. This long-term follow-up study indicates that CR-CHOP in untreated DLBCL with the DEL phenotype demonstrates high short-term efficacy and safety as well as promising survival outcomes.
Journal • Real-world evidence • IO biomarker • Real-world effectiveness • Real-world
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
10d
New trial
|
Epidaza (chidamide) • Folotyn (pralatrexate)
11d
Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. (PubMed, J Control Release)
In TRAIL-sensitive colon cancer cells (COLO205, HCT-116), P-cDR5 showed efficacy comparable to anti-DR5 mAb Drozitumab (DRO), but P-cDR5 outperformed DRO in TRAIL-resistant cells (HT-29), highlighting the importance of efficient receptor clustering...Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted in further enhancement of apoptosis inducing efficacy, along with destabilizing mitochondrial membranes and increased sensitivity of TRAIL-resistant cells. These findings suggest that attaching multiple cDR5 peptides to a flexible water-soluble polymer carrier not only overcomes the limitations of previous designs but also offers a promising avenue for treating resistant cancers, pointing toward the need for further preclinical exploration and validation of this innovative strategy.
Journal • Epigenetic controller
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
drozitumab (RG7425)
11d
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. (PubMed, Cell Death Dis)
Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression.
Journal • Tumor cell
|
DNMT1 (DNA methyltransferase 1)
|
DNMT1 expression
|
Mekinist (trametinib) • cisplatin • Zolinza (vorinostat)
12d
Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. (PubMed, Gut)
Our immunoepigenetic strategy harnesses IFNγ-mediated network to augment the cancer-immunity cycle, revealing a self-reinforcing STAT1-GSDME pyroptotic circuitry as the mechanistic basis for an ongoing phase-II trial to tackle ICB resistance (NCT05873244).
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B) • HDAC1 (Histone Deacetylase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • GSDME (Gasdermin E)
|
Keytruda (pembrolizumab) • zabinostat (CXD101)
14d
Chidamide Combined with (+) -JQ-1 to Kill MLL-Rearrangement Acute Myeloid Leukemia Cells by Disrupting the DNA Damage Response Pathway (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Chidamide combined with (+)-JQ-1 can inhibit the proliferation of MLL-r AML cells, inhibit the initiation of protective self-repair of these leukemia cells by inhibiting the DNA damage response pathway, and ultimately increase the apoptosis of these cells, but non- MLL-r AML cells have no similar results.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BRD4 (Bromodomain Containing 4) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
MLL rearrangement • MLL rearrangement • BCL2 expression • BAX expression
|
JQ-1 • Epidaza (chidamide)
14d
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=93, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi)
15d
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Kisqali (ribociclib) • Beleodaq (belinostat)
16d
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 23 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Istodax (romidepsin) • fludarabine IV • busulfan
21d
Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma/leukemia via the FOXO1/GSDME axis. (PubMed, Chin Med J (Engl))
Our study suggested that chidamide exerts an antitumor effect on T-LBL/ALL and promotes a more inflammatory form of cell death via the FOXO1/GSDME axis, which provides a novel choice of targeted therapy for patients with T-LBL/ALL.
Journal
|
CASP3 (Caspase 3) • FOXO1 (Forkhead box O1) • HDAC2 (Histone deacetylase 2) • HDAC1 (Histone Deacetylase 1) • GSDME (Gasdermin E) • HDAC3 (Histone Deacetylase 3)
|
Epidaza (chidamide)
22d
Enrollment open
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
RAS wild-type • EZH2 mutation • EZH2 wild-type
|
Tazverik (tazemetostat) • Beleodaq (belinostat)
22d
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma. (PubMed, J Exp Clin Cancer Res)
These findings demonstrate that ERAP1 inhibition combined with HDACi entinostat treatment and PD-1 blockade remodels the immune landscape of a non-immunogenic tumor such as NB, making it responsive to checkpoint immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD4 (CD4 Molecule) • CASP3 (Caspase 3) • ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) • CASP7 (Caspase 7)
|
Jingzhuda (entinostat)
22d
R-ICE+X: Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=76, Recruiting, Ruijin Hospital | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date
|
carboplatin • Brukinsa (zanubrutinib) • decitabine • Epidaza (chidamide) • pomalidomide • tofacitinib
23d
Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome. (PubMed, Neurooncol Adv)
Potential maintenance regimens may include low-dose traditional chemotherapy or different epigenetic therapies designed to target the epigenetic imbalance that drives RTs. We here review several potential maintenance regimens that may be useful in RTPS.
Review • Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
Tazverik (tazemetostat) • Farydak (panobinostat)
23d
Development of a prognostic model related to homologous recombination deficiency in glioma based on multiple machine learning. (PubMed, Front Immunol)
Molecular docking highlighted several compounds, notably Panobinostat, as promising for high-risk patients. The prognostic model based on the HRD score threshold and associated genes in glioma offers new insights into the genomic and immunological landscapes, potentially guiding therapeutic strategies. The differential immune profiles associated with HRD-risk groups could inform immunotherapeutic interventions, with our findings paving the way for personalized medicine in glioma treatment.
Journal • IO biomarker • Machine learning
|
HRD (Homologous Recombination Deficiency)
|
HRD • High HRD score
|
Farydak (panobinostat)
24d
New trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
24d
NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target. (PubMed, Int J Biol Sci)
In this study, by conducting bioinformatics analyses as well as in vitro and in vivo experiments, we identified that NUSAP1 was significantly upregulated in LUAD, with a notable correlation with poorer overall survival, higher scores for immunogenicity and immune infiltration, as well as increased sensitivity to conventional chemotherapeutic drugs such as paclitaxel, docetaxel and vinorelbine in LUAD. Furthermore, we identified entinostat as a novel inhibitor of NUSAP1. Pharmacological targeting ERβ/NUSAP1 axis with fulvestrant (ERβ antagonist) or entinostat (novel NUSAP1 inhibitor) significantly reduced LUAD growth both in vitro and in vivo, which may represent effective alternative therapeutic strategies for patients with LUAD.
Journal
|
NUSAP1 (Nucleolar and Spindle Associated Protein 1)
|
NUSAP1 overexpression
|
paclitaxel • docetaxel • fulvestrant • vinorelbine tartrate • Jingzhuda (entinostat)
24d
MEF2C is a Potential Prognostic Biomarker and is Correlated with Immune Infiltrates in Lung Adenocarcinoma. (PubMed, Curr Med Chem)
The results imply that MEF2C could be a valuable indicator for predicting outcomes and a possible target for immunotherapy for LUAD patients.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • MEF2C (Myocyte Enhancer Factor 2C)
|
Tasigna (nilotinib) • irinotecan • topotecan • Farydak (panobinostat)
24d
Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis. (PubMed, Cancer Lett)
Mechanistically, our data point to NRP1 mediating this effect via the down regulation of migration machinery, namely SRC, FAK and ROCK1 expression/activity, that is in part, related to NRP1 interaction with integrin beta 1 (ITGB1). In summary, our data indicate that romidepsin down regulation of NRP1 significantly mitigates the ability of OS cells to seed the lung and establish metastases, and that targeting NRP1 or its effectors with selective inhibitors may be a viable means with which to prevent this deadly aspect of the disease.
Journal • Epigenetic controller
|
NRP1 (Neuropilin 1) • ITGB1 (Integrin Subunit Beta 1) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
|
Istodax (romidepsin)
28d
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy. (PubMed, ACS Pharmacol Transl Sci)
When combined with the anti-HCC drug sorafenib, STR-V-53, showed greater in vivo efficacy...Transcriptomic analysis revealed that STR-V-53 primed HCC cells to immunotherapy through HDAC inhibition, impaired glucose-regulated transcription, impaired DNA synthesis, upregulated apoptosis, and stimulated the immune response pathway. Collectively, our data demonstrate that the novel HDACi STR-V-53 is an effective anti-HCC agent that can induce profound responses when combined with standard immunotherapy.
Journal • Epigenetic controller
|
CD8 (cluster of differentiation 8)
|
sorafenib
28d
Low-Dose Treatment with Epirubicin, a Novel Histone Deacetylase 1 Inhibitor, Exerts Anti-leukemic Effects by Inducing Ferroptosis. (PubMed, Eur J Pharmacol)
Our study demonstrated that Epi might be used as a HDAC1 inhibitor. Low-dose Epi could inhibit tumor progression by inducing cell ferroptosis in vitro and in vivo. Thus, Epi administration with lower concentration may be much more favorable and safer in the treatment with leukemia.
Journal • Epigenetic controller
|
HDAC1 (Histone Deacetylase 1)
|
epirubicin • Epidaza (chidamide) • Zolinza (vorinostat)
29d
Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas. (PubMed, Cancer Rep (Hoboken))
Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.
Journal
|
BECN1 (Beclin 1)
|
cisplatin • cyclophosphamide • etoposide IV • Zolinza (vorinostat)
29d
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer. (PubMed, Cancers (Basel))
The triple combination of entinostat, a BETi, and cisplatin is highly synergistic, reverses cisplatin resistance, and may thus serve as a novel therapeutic approach for bladder cancer.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
cisplatin • JQ-1 • birabresib (OTX015) • Jingzhuda (entinostat)
29d
Design, Synthesis, and Biological Evaluation of HDAC Inhibitors Containing Natural Product-Inspired N-Linked 2-Acetylpyrrole Cap. (PubMed, Molecules)
Among them, compound 20 exhibited potential inhibitory activity on HDAC1, and demonstrated notable potency against RPMI-8226 cells with an IC50 value of 2.89 ± 0.43 μM, which was better than chidamide (IC50 = 10.23 ± 1.02 μM)...The ADME parameters calculation showed that 20 possesses remarkable theoretical drug-likeness properties. Taken together, these results suggested that 20 is worthy of further exploration as a potential HDAC-targeted anticancer drug candidate.
Journal
|
HDAC1 (Histone Deacetylase 1) • ANXA5 (Annexin A5)
|
Epidaza (chidamide)
1m
New P2 trial • Metastases
|
Epidaza (chidamide) • Yidafan (ivonescimab)
1m
Polydatin inhibits histone deacetylase 1 and shows an anti-angiogenic action in head and neck squamous cell carcinoma. (PubMed, Med Oncol)
Further, the cell death was more pronounced with SAHA treatment. Therefore, polydatin might be a better anticancer drug and can have a potential to replace SAHA in combinational therapeutic regimen.
Journal • Epigenetic controller
|
THBS1 (Thrombospondin 1) • HDAC1 (Histone Deacetylase 1)
|
Zolinza (vorinostat)
1m
Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis. (PubMed, Bioorg Med Chem Lett)
Further molecular docking experiments illustrated the potential interactions between compound 11g and HDAC1. These findings suggested that the novel Tetrahydro-β-carboline-based HDACis could serve as a promising framework for further optimization as anticancer agents.
Journal • Tumor cell
|
HDAC1 (Histone Deacetylase 1)
1m
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer. (PubMed, Apoptosis)
18A possessed similar HDAC inhibitory activity as MS-275 and potently suppressed CDC25 activity in vitro and the CDK1 dephosphorylation in cells. Additionally, 18A hindered the progression of S and G2/M phases, triggered DNA damage, and induced apoptosis. These findings underscore the potential of 18A as a targeted therapy for TNBC and warrants further preclinical development.
Journal
|
CDK1 (Cyclin-dependent kinase 1) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
Jingzhuda (entinostat)
1m
Study of TRAIL and SAHA Co-Treatment on Leukemia K562 Cell Line. (PubMed, Cell Biochem Biophys)
Furthermore, it was shown that DR4, DR5, and CHOP expressions were enhanced, and PI3K, Akt, ERK, STAT3, c-FLIPL, NF-κB, and BCR-ABL expressions were decreased by SAHA in K562 cells. Our study indicated that SAHA combined with TRAIL can increase the sensitivity of K562 leukemic cells to TRAIL by suppressing intracellular anti-apoptotic molecules and augmenting the expressions of DR4/DR5 and CHOP.
Preclinical • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • STAT3 (Signal Transducer And Activator Of Transcription 3) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CFLAR (CASP8 and FADD-like apoptosis regulator) • ANXA5 (Annexin A5) • PI3K (Phosphoinositide 3-kinases)
|
Zolinza (vorinostat)
1m
Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. (PubMed, Proc Natl Acad Sci U S A)
Finally, we showed that T cells contribute to in vivo tumor growth control in the presence of entinostat and trametinib combination treatment. Together, our findings reveal that HDAC3 is a druggable endogenous repressor of T cell recruitment into Kras mutant lung tumors.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • HDAC3 (Histone Deacetylase 3)
|
KRAS mutation • CXCL10 expression
|
Mekinist (trametinib) • Jingzhuda (entinostat)
1m
HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma. (PubMed, J Immunother Cancer)
Our results revealed a novel mechanism by which the HDACi SAHA potentiates CD8+T-cell-mediated antitumor activity through the HDAC1/JAK1/FGL1 axis, providing a rationale for the combined use of HDACis and immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HDAC1 (Histone Deacetylase 1) • FGL1 (Fibrinogen Like 1)
|
Zolinza (vorinostat)
1m
Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation. (PubMed, Int Immunopharmacol)
ZDLT-1 as HDAC inhibitor could suppresses CRC cell growth in vivo and in vitro by triggering HIF-1α/Caspase-3/Caspase-9 pathway in promoting apoptosis, and triggering NF-κB/GSDMD/GSDME pathway in inhibiting tumor inflammation. Our results propose dehydroharmine derivative ZDLT-1 as a promising therapeutic small molecular agent for CRC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • ANXA5 (Annexin A5) • GSDME (Gasdermin E)
|
HIF1A expression
1m
Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity. (PubMed, J Enzyme Inhib Med Chem)
Moreover, 19 exhibited better metabolic stability in vitro than SAHA. Our study demonstrated that compound 19 was a promising candidate for further preclinical studies.
Journal
|
JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1)
|
Zolinza (vorinostat)